carbostyril has been researched along with Acute Lymphoid Leukemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eucker, J; Habbel, P; Li, X; Liu, H; Scholz, C; Schulz, CO; Zang, C; Zhou, Y | 1 |
| Marks, DI | 1 |
| Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S | 1 |
| Zhang, GS | 1 |
| Creutzig, U; Gibson, BE; Goemans, BF; Hählen, K; Harlow, A; Heinrich, MC; Kaspers, GJ; Loonen, AH; Reinhardt, D; Zwaan, CM | 1 |
| Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ | 1 |
1 review(s) available for carbostyril and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
The challenges of managing older patients with acute lymphoblastic leukemia.
Topics: Age Distribution; Aged; Antineoplastic Agents; Bacterial Infections; Female; Forecasting; Geriatric Assessment; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm, Residual; Patient Care Planning; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Randomized Controlled Trials as Topic; Renal Insufficiency; Sex Distribution; Survival Analysis; Transplantation, Autologous; United Kingdom | 2015 |
2 trial(s) available for carbostyril and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones | 2011 |
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome | 2001 |
3 other study(ies) available for carbostyril and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Drug Synergism; Everolimus; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Inhibitory Concentration 50; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolones; Sirolimus; TOR Serine-Threonine Kinases; Translocation, Genetic | 2014 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Topics: Adolescent; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Farnesyltranstransferase; Female; Humans; Leukemia, Monocytic, Acute; Male; Mutation; Oncogene Protein p21(ras); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinolones; Tumor Cells, Cultured | 2005 |